NovoCure Limited (NVCR) Operating margin 2017–2026
NovoCure Limited (NVCR) operating margin by fiscal year — reported operating income divided by reported revenue.
-23.5%FY2026 · since FY2017: -139.1% → -23.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -23.5% | +4.7 pp |
| FY2025 | -28.2% | +17.5 pp |
| FY2024 | -45.7% | -29.1 pp |
| FY2023 | -16.6% | -8.4 pp |
| FY2022 | -8.3% | -14.4 pp |
| FY2021 | 6.1% | +6.4 pp |
| FY2020 | -0.3% | +13.3 pp |
| FY2019 | -13.6% | +8.6 pp |
| FY2018 | -22.2% | +116.9 pp |
| FY2017 | -139.1% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVCR financial trends
NVCR RevenueNVCR Net incomeNVCR Net marginNVCR Gross profitNVCR Gross marginNVCR Operating incomeNVCR Operating cash flowNVCR Free cash flowNVCR Capital expendituresNVCR Return on equityNVCR Stock buybacksNVCR Dividends paidNVCR Total assetsNVCR Total liabilitiesNVCR Shareholders’ equityNVCR overview →